Condition: Enteric Hyperoxaluria · Sponsor: Allena Pharmaceuticals
The purpose of this study is to determine the efficacy and safety of ALLN-177 in patients with enteric hyperoxaluria.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Urology Centers of Alabama | Birmingham, Alabama, United States | — |
| University of Alabama, Department of Urology | Birmingham, Alabama, United States | — |
| Mayo Clinic Hospital | Phoenix, Arizona, United States | — |
| Urological Associates of Southern Arizona | Tucson, Arizona, United States | — |
| Applied Research Center of Arkansas | Little Rock, Arkansas, United States | — |
| TROVARE Clinical Research | Bakersfield, California, United States | — |
| Advanced Urology Institute | Daytona Beach, Florida, United States | — |
| Mayo Clinic - Jacksonville | Jacksonville, Florida, United States | — |
| Center for Advanced GI (CFAGI) | Maitland, Florida, United States | — |
| South Medical Research Group, Inc. | Miami, Florida, United States | — |
| North Idaho Urology | Coeur d'Alene, Idaho, United States | — |
| Idaho Urologic Institue | Meridian, Idaho, United States | — |
+ 51 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03456830